MCDC

8/11 2022

Medical Innovation Challenge announces contenders for $200,000 award

2022-08-17T17:53:37+00:00August 11th, 2022|Press Releases|

Advanced Technology International (ATI) and TechConnect today announced 25 finalists who will pitch on September 28, 2022 at Defense TechConnect Innovation Summit for $200,000 in non-dilutive awards. These candidates receive membership from four consortia with a combined $50B in federal contracting authority including: Medical CBRN Defense Consortium (MCDC), Countering Weapons of Mass Destruction Consortium (CWMD), Medical Technology Enterprise Consortium (MTEC), and Senior Healthcare Innovation Consortium (SHIC).

12/2 2021

Pulmotect provides results from two randomized, placebo controlled phase-2 trials of PUL-042 against COVID-19

2021-12-06T13:11:46+00:00December 2nd, 2021|ATI in the News|

In the two Phase 2 trials, PUL-042 was evaluated in one trial as preemptive treatment in patients with early, symptomatic infection and in a second trial in the prophylactic settings in subjects with known exposure to SARS-CoV-2. The Phase 2 studies of PUL-042 for COVID-19 are funded in part with federal funds from the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), through the U.S. Army Contracting Command - New Jersey, under an Other Transaction Agreement (W15QKN-16-9-1002, Project #MCDC 2006-002) awarded to the Medical CBRN Defense Consortium and Pulmotect, Inc.

9/21 2021

Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19

2021-09-22T12:28:01+00:00September 21st, 2021|ATI in the News|

Pulmotect, Inc., a clinical-stage biotechnology company, announced positive topline results from the first of two Phase-2 clinical trials undertaken with the support of the US Department of Defense (DOD) to evaluate PUL-042 against COVID-19. The Phase 2 studies of PUL-042 for COVID-19 are funded in part with federal funds from the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM CBRN Medical), through the U.S. Army Contracting Command - New Jersey, under an Other Transaction Agreement (W15QKN-16-9-1002, Project #MCDC 2006-002) awarded to the Medical CBRN Defense Consortium and Pulmotect, Inc.

6/4 2021

MCDC member receives DoD funding for Phase-2 trials of PUL-042 against COVID-19

2021-09-22T12:31:04+00:00June 4th, 2021|Success Stories|

Pulmotect, Inc., a clinical-stage biotechnology company and non-traditional Medical CBRN Defense Consortium (MCDC) member, is joining the fight against COVID-19.

3/20 2020

Coronavirus pandemic solutions sought by government; MCDC releases Request for Information

2021-07-02T20:33:39+00:00March 20th, 2020|News|

Medical CBRN Defense Consortium (MCDC) has released a Request for Information (RFI) seeking solutions to combat the novel Coronavirus (2019-nCoV) pandemic.

Go to Top